Co-administration phenoxodiol with doxorubicin synergistically inhibit the activity of sphingosine kinase-1 (SphK1), a potential oncogene of osteosarcoma, to suppress osteosarcoma cell growth both in vivo and in vitro

Molecular Oncology

Volumn 6, Issue 4, 2012, Pages 392-404

  Yao, Chen ^a   Wu, Sujia ^b   Li, Dong ^a   Ding, Huimin ^a   Wang, Zuyu ^a   Yang, Yongjiang ^a   Yan, Shichang ^a   Gu, Zhangping ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING GENERAL HOSPITAL OF NANJING MILITARY COMMAND   (China)

Author keywords

Chemotherapy; Doxorubicin; Osteosarcoma; Phenoxodiol; Signal transduction; Sphingosine kinase 1

Indexed keywords

CERAMIDE; DOXORUBICIN; IDRONOXIL; PHOSPHOPROTEIN PHOSPHATASE 1; PROTEIN KINASE B; SHORT HAIRPIN RNA; SPHINGOSINE KINASE 1; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

MUS;

EID: 84864292058     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2012.04.002     Document Type: Article

References (41)

1. Alemany R., van Koppen C.J., Danneberg K., Ter Braak M., Meyer Zu Heringdorf D. Regulation and functional roles of sphingosine kinases. Naunyn. Schmiedebergs. Arch. Pharmacol. 2007, 374:413-428.
2. Babia T., Veldman R.J., Hoekstra D., Kok J.W. Modulation of carcinoembryonic antigen release by glucosylceramide - implications for HT29 cell differentiation. Eur. J. Biochem. 1998, 258:233-242.
3. Banerjee S., Li Y., Wang Z., Sarkar F.H. Multi-targeted therapy of cancer by genistein. Cancer Lett. 2008, 269:226-242.
4. Basu S., Kolesnick R. Stress signals for apoptosis: ceramide and c-Jun kinase. Oncogene 1998, 17:3277-3285.
5. Cenni V., Maraldi N.M., Ruggeri A., Secchiero P., Del Coco R., De Pol A., Cocco L., Marmiroli S. Sensitization of multidrug resistant human osteosarcoma cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of the Akt/PKB kinase. Int. J. Oncol. 2004, 25:1599-1608.
6. Chou A.J., Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev. Anticancer Ther. 2006, 6:1075-1085.
7. Dobrowsky R.T., Kamibayashi C., Mumby M.C., Hannun Y.A. Ceramide activates heterotrimeric protein phosphatase 2A. J. Biol. Chem. 1993, 268:15523-15530.
8. Gamble J.R., Xia P., Hahn C.N., Drew J.J., Drogemuller C.J., Brown D., Vadas M.A. Phenoxodiol, an experimental anticancer drug, shows potent antiangiogenic properties in addition to its antitumour effects. Int. J. Cancer 2006, 118:2412-2420.
9. Hait N.C., Sarkar S., Le Stunff H., Mikami A., Maceyka M., Milstien S., Spiegel S. Role of sphingosine kinase 2 in cell migration toward epidermal growth factor. J. Biol. Chem. 2005, 280:29462-29469.
10. Ji C., Yang B., Yang Y.L., He S.H., Miao D.S., He L., Bi Z.G. Exogenous cell-permeable C6 ceramide sensitizes multiple cancer cell lines to Doxorubicin-induced apoptosis by promoting AMPK activation and mTORC1 inhibition. Oncogene 2010, 29:6557-6568.
11. Jin S., Pang R.P., Shen J.N., Huang G., Wang J., Zhou J.G. Grifolin induces apoptosis via inhibition of PI3K/AKT signalling pathway in human osteosarcoma cells. Apoptosis 2007, 12:1317-1326.
12. Kamsteeg M., Rutherford T., Sapi E., Hanczaruk B., Shahabi S., Flick M., Brown D., Mor G. Phenoxodiol - an isoflavone analog - induces apoptosis in chemoresistant ovarian cancer cells. Oncogene 2003, 22:2611-2620.
13. Kandaswami C., Lee L.T., Lee P.P., Hwang J.J., Ke F.C., Huang Y.T., Lee M.T. The antitumor activities of flavonoids. In Vivo 2005, 19:895-909.
14. Kolesnick R.N., Kronke M. Regulation of ceramide production and apoptosis. Annu. Rev. Physiol. 1998, 60:643-665.
15. Lamartiniere C.A., Murrill W.B., Manzolillo P.A., Zhang J.X., Barnes S., Zhang X., Wei H., Brown N.M. Genistein alters the ontogeny of mammary gland development and protects against chemically-induced mammary cancer in rats. Proc. Soc. Exp. Biol. Med. 1998, 217:358-364.
16. Law B., Rossie S. The dimeric and catalytic subunit forms of protein phosphatase 2A from rat brain are stimulated by C2-ceramide. J. Biol. Chem. 1995, 270:12808-12813.
17. Liu B., Shi Z.L., Feng J., Tao H.M. Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt. Cell Biol. Int. 2008, 32:494-501.
18. Liu X., Ryland L., Yang J., Liao A., Aliaga C., Watts R., Tan S.F., Kaiser J., Shanmugavelandy S.S., Rogers A., Loughran K., Petersen B., Yuen J., Meng F., Baab K.T., Jarbadan N.R., Broeg K., Zhang R., Liao J., Sayers T.J., Kester M., Loughran T.P. Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. Blood 2010, 116:4192-4201.
19. Maceyka M., Payne S.G., Milstien S., Spiegel S. Sphingosine kinase, sphingosine-1-phosphate, and apoptosis. Biochim. Biophys. Acta 2002, 1585:193-201.
20. Merrill A.H., van Echten G., Wang E., Sandhoff K. Fumonisin B1 inhibits sphingosine (sphinganine) N-acyltransferase and de novo sphingolipid biosynthesis in cultured neurons in situ. J. Biol. Chem. 1993, 268:27299-27306.
21. Miltyk W., Craciunescu C.N., Fischer L., Jeffcoat R.A., Koch M.A., Lopaczynski W., Mahoney C., Jeffcoat R.A., Crowell J., Paglieri J., Zeisel S.H. Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer. Am. J. Clin. Nutr. 2003, 77:875-882.
22. Mor G., Fu H.H., Alvero A.B. Phenoxodiol, a novel approach for the treatment of ovarian cancer. Curr. Opin. Investig. Drugs 2006, 7:542-548.
23. Ogretmen B., Hannun Y.A. Updates on functions of ceramide in chemotherapy-induced cell death and in multidrug resistance. Drug Resist. Updat. 2001, 4:368-377.
24. Okada T., Kajimoto T., Jahangeer S., Nakamura S. Sphingosine kinase/sphingosine 1-phosphate signalling in central nervous system. Cell. Signal. 2009, 21:7-13.
25. Panaretakis T., Laane E., Pokrovskaja K., Bjorklund A.C., Moustakas A., Zhivotovsky B., Heyman M., Shoshan M.C., Grander D. Doxorubicin requires the sequential activation of caspase-2, protein kinase Cdelta, and c-Jun NH2-terminal kinase to induce apoptosis. Mol. Biol. Cell 2005, 16:3821-3831.
26. Park J.H., Sihn C.R., Lee Y.S., Lee S.J., Kim S.H. Depletion of neuroguidin/CANu1 sensitizes human osteosarcoma U2OS cells to doxorubicin. BMB Rep. 2011, 44:46-51.
27. Paugh B.S., Paugh S.W., Bryan L., Kapitonov D., Wilczynska K.M., Gopalan S.M., Rokita H., Milstien S., Spiegel S., Kordula T. EGF regulates plasminogen activator inhibitor-1 (PAI-1) by a pathway involving c-Src, PKCdelta, and sphingosine kinase 1 in glioblastoma cells. FASEB J. 2008, 22:455-465.
28. Reynolds C.P., Maurer B.J., Kolesnick R.N. Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett. 2004, 206:169-180.
29. Sabbadini R.A. Targeting sphingosine-1-phosphate for cancer therapy. Br. J. Cancer 2006, 95:1131-1135.
30. Sarkar F.H., Li Y. Soy isoflavones and cancer prevention. Cancer Invest. 2003, 21:744-757.
31. Shida D., Takabe K., Kapitonov D., Milstien S., Spiegel S. Targeting SphK1 as a new strategy against cancer. Curr. Drug Targets 2008, 9:662-673.
32. Silasi D.A., Alvero A.B., Rutherford T.J., Brown D., Mor G. Phenoxodiol: pharmacology and clinical experience in cancer monotherapy and in combination with chemotherapeutic drugs. Expert Opin. Pharmacother. 2009, 10:1059-1067.
33. Tagaram H.R., Divittore N.A., Barth B.M., Kaiser J.M., Avella D., Kimchi E.T., Jiang Y., Isom H.C., Kester M., Staveley-O'Carroll K.F. Nanoliposomal ceramide prevents in vivo growth of hepatocellular carcinoma. Gut 2011, 60:695-701.
34. Takimoto C.H., Glover K., Huang X., Hayes S.A., Gallot L., Quinn M., Jovanovic B.D., Shapiro A., Hernandez L., Goetz A., Llorens V., Lieberman R., Crowell J.A., Poisson B.A., Bergan R.C. Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer. Cancer Epidemiol. Biomarkers Prev. 2003, 12:1213-1221.
35. Tobiume K., Matsuzawa A., Takahashi T., Nishitoh H., Morita K., Takeda K., Minowa O., Miyazono K., Noda T., Ichijo H. ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep. 2001, 2:222-228.
36. Vadas M., Xia P., McCaughan G., Gamble J. The role of sphingosine kinase 1 in cancer: oncogene or non-oncogene addiction?. Biochim. Biophys. Acta 2008, 1781:442-447.
37. van Lummel M., van Blitterswijk W.J., Vink S.R., Veldman R.J., van der Valk M.A., Schipper D., Dicheva B.M., Eggermont A.M., ten Hagen T.L., Verheij M., Koning G.A. Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors. FASEB J. 2011, 25:280-289.
38. Verheij M., Bose R., Lin X.H., Yao B., Jarvis W.D., Grant S., Birrer M.J., Szabo E., Zon L.I., Kyriakis J.M., Haimovitz-Friedman A., Fuks Z., Kolesnick R.N. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 1996, 380:75-79.
39. Wolff R.A., Dobrowsky R.T., Bielawska A., Obeid L.M., Hannun Y.A. Role of ceramide-activated protein phosphatase in ceramide-mediated signal transduction. J. Biol. Chem. 1994, 269:19605-19609.
40. Yu S., Shen G., Khor T.O., Kim J.H., Kong A.N. Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism. Mol. Cancer Ther. 2008, 7:2609-2620.
41. Zhu Q.Y., Wang Z., Ji C., Cheng L., Yang Y.L., Ren J., Jin Y.H., Wang Q.J., Gu X.J., Bi Z.G., Hu G., Yang Y. C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and alpha-tubulin hyperacetylation both in vitro and in vivo. Cell Death Dis. 2011, 2:e117.